BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 31675229)

  • 1. Drug Design Targeting T-Cell Factor-Driven Epithelial-Mesenchymal Transition as a Therapeutic Strategy for Colorectal Cancer.
    Abraham AD; Esquer H; Zhou Q; Tomlinson N; Hamill BD; Abbott JM; Li L; Pike LA; Rinaldetti S; Ramirez DA; Lunghofer PJ; Gomez JD; Schaack J; Nemkov T; D'Alessandro A; Hansen KC; Gustafson DL; Messersmith WA; LaBarbera DV
    J Med Chem; 2019 Nov; 62(22):10182-10203. PubMed ID: 31675229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Topoisomerase IIα mediates TCF-dependent epithelial-mesenchymal transition in colon cancer.
    Zhou Q; Abraham AD; Li L; Babalmorad A; Bagby S; Arcaroli JJ; Hansen RJ; Valeriote FA; Gustafson DL; Schaack J; Messersmith WA; LaBarbera DV
    Oncogene; 2016 Sep; 35(38):4990-9. PubMed ID: 26947016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-in-Class Inhibitors of Oncogenic CHD1L with Preclinical Activity against Colorectal Cancer.
    Abbott JM; Zhou Q; Esquer H; Pike L; Broneske TP; Rinaldetti S; Abraham AD; Ramirez DA; Lunghofer PJ; Pitts TM; Regan DP; Tan AC; Gustafson DL; Messersmith WA; LaBarbera DV
    Mol Cancer Ther; 2020 Aug; 19(8):1598-1612. PubMed ID: 32499299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DNA topoisomerase 1 and 2A function as oncogenes in liver cancer and may be direct targets of nitidine chloride.
    Liu LM; Xiong DD; Lin P; Yang H; Dang YW; Chen G
    Int J Oncol; 2018 Nov; 53(5):1897-1912. PubMed ID: 30132517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regorafenib (Stivarga) pharmacologically targets epithelial-mesenchymal transition in colorectal cancer.
    Fan LC; Teng HW; Shiau CW; Tai WT; Hung MH; Yang SH; Jiang JK; Chen KF
    Oncotarget; 2016 Sep; 7(39):64136-64147. PubMed ID: 27580057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel indeno[1,2-b]pyridinone derivative, a DNA intercalative human topoisomerase IIα catalytic inhibitor, for caspase 3-independent anticancer activity.
    Jeon KH; Park C; Kadayat TM; Shrestha A; Lee ES; Kwon Y
    Chem Commun (Camb); 2017 Jun; 53(51):6864-6867. PubMed ID: 28604852
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis, biological evaluation, structure-activity relationship study, and mode of action of 2-phenol-4,6-dichlorophenyl-pyridines.
    Shrestha A; Park S; Shin S; Man Kadayat T; Bist G; Katila P; Kwon Y; Lee ES
    Bioorg Chem; 2018 Sep; 79():1-18. PubMed ID: 29715635
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resveratrol suppresses epithelial-to-mesenchymal transition in colorectal cancer through TGF-β1/Smads signaling pathway mediated Snail/E-cadherin expression.
    Ji Q; Liu X; Han Z; Zhou L; Sui H; Yan L; Jiang H; Ren J; Cai J; Li Q
    BMC Cancer; 2015 Mar; 15():97. PubMed ID: 25884904
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis, computational quantum chemical study, in silico ADMET and molecular docking analysis, in vitro biological evaluation of a novel sulfur heterocyclic thiophene derivative containing 1,2,3-triazole and pyridine moieties as a potential human topoisomerase IIα inhibiting anticancer agent.
    Murugavel S; Ravikumar C; Jaabil G; Alagusundaram P
    Comput Biol Chem; 2019 Apr; 79():73-82. PubMed ID: 30731361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clarifying the Mechanism of Copper(II) α-(N)-Heterocyclic Thiosemicarbazone Complexes on DNA Topoisomerase IIα and IIβ.
    Keck JM; Conner JD; Wilson JT; Jiang X; Lisic EC; Deweese JE
    Chem Res Toxicol; 2019 Oct; 32(10):2135-2143. PubMed ID: 31512855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PARP3 controls TGFβ and ROS driven epithelial-to-mesenchymal transition and stemness by stimulating a TG2-Snail-E-cadherin axis.
    Karicheva O; Rodriguez-Vargas JM; Wadier N; Martin-Hernandez K; Vauchelles R; Magroun N; Tissier A; Schreiber V; Dantzer F
    Oncotarget; 2016 Sep; 7(39):64109-64123. PubMed ID: 27579892
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polyamine-containing etoposide derivatives as poisons of human type II topoisomerases: Differential effects on topoisomerase IIα and IIβ.
    Oviatt AA; Kuriappan JA; Minniti E; Vann KR; Onuorah P; Minarini A; De Vivo M; Osheroff N
    Bioorg Med Chem Lett; 2018 Sep; 28(17):2961-2968. PubMed ID: 30006062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional interaction of DNA topoisomerase IIalpha with the beta-catenin and T-cell factor-4 complex.
    Huang L; Shitashige M; Satow R; Honda K; Ono M; Yun J; Tomida A; Tsuruo T; Hirohashi S; Yamada T
    Gastroenterology; 2007 Nov; 133(5):1569-78. PubMed ID: 17983804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel nalidixic acid derivatives targeting topoisomerase II enzyme; Design, synthesis, anticancer activity and effect on cell cycle profile.
    Khalil OM; Gedawy EM; El-Malah AA; Adly ME
    Bioorg Chem; 2019 Mar; 83():262-276. PubMed ID: 30391699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Top2a identifies and provides epigenetic rationale for novel combination therapeutic strategies for aggressive prostate cancer.
    Kirk JS; Schaarschuch K; Dalimov Z; Lasorsa E; Ku S; Ramakrishnan S; Hu Q; Azabdaftari G; Wang J; Pili R; Ellis L
    Oncotarget; 2015 Feb; 6(5):3136-46. PubMed ID: 25605014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The catalytic topoisomerase II inhibitor dexrazoxane induces DNA breaks, ATF3 and the DNA damage response in cancer cells.
    Deng S; Yan T; Nikolova T; Fuhrmann D; Nemecek A; Gödtel-Armbrust U; Kaina B; Wojnowski L
    Br J Pharmacol; 2015 May; 172(9):2246-57. PubMed ID: 25521189
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Topoisomerase-1 and -2A gene copy numbers are elevated in mismatch repair-proficient colorectal cancers.
    Sønderstrup IM; Nygård SB; Poulsen TS; Linnemann D; Stenvang J; Nielsen HJ; Bartek J; Brünner N; Nørgaard P; Riis L
    Mol Oncol; 2015 Jun; 9(6):1207-17. PubMed ID: 25777966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Topoisomerase IIα represses transcription by enforcing promoter-proximal pausing.
    Herrero-Ruiz A; Martínez-García PM; Terrón-Bautista J; Millán-Zambrano G; Lieberman JA; Jimeno-González S; Cortés-Ledesma F
    Cell Rep; 2021 Apr; 35(2):108977. PubMed ID: 33852840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PRRX1-TOP2A interaction is a malignancy-promoting factor in human malignant peripheral nerve sheath tumours.
    Takihira S; Yamada D; Osone T; Takao T; Sakaguchi M; Hakozaki M; Itano T; Nakata E; Fujiwara T; Kunisada T; Ozaki T; Takarada T
    Br J Cancer; 2024 May; 130(9):1493-1504. PubMed ID: 38448751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design, synthesis, topoisomerase I & II inhibitory activity, antiproliferative activity, and structure-activity relationship study of pyrazoline derivatives: An ATP-competitive human topoisomerase IIα catalytic inhibitor.
    Ahmad P; Woo H; Jun KY; Kadi AA; Abdel-Aziz HA; Kwon Y; Rahman AF
    Bioorg Med Chem; 2016 Apr; 24(8):1898-908. PubMed ID: 26988802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.